Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (USAN)

+ [10]

Target

PD-1

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Malignant Pleural MesotheliomaUnresectable Urothelial CarcinomaAdvanced Endometrial Carcinoma+ [505]

Inactive Indication

Acute lymphoblastic leukemia recurrentAdenocarcinoma, metastaticAdenoviridae Infections+ [68]

Originator Organization

Merck & Co., Inc.

Active Organization

National Cancer Institute

Merck Sharp & Dohme Corp.

Mayo Clinic

+ [82]

Inactive Organization

Daiichi Sankyo, Inc.

Rainier Therapeutics, Inc.

Nektar Therapeutics

+ [13]

Drug Highest PhaseApproved

First Approval Date

US (04 Sep 2014),

Melanoma

RegulationConditional marketing approval (CN), PRIME (EU), Orphan Drug (JP), Priority Review (AU), Breakthrough Therapy (US), Accelerated Approval (US)

Login to view timeline

Gene Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol).
Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors:
* Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer)
* ECOG score at baseline (0 vs 1)
* Geographic region (Asia vs ROW)

Start Date01 Dec 2025

Sponsor / Collaborator

Evergreen Therapeutics, Inc

NCT05106127 / Not yet recruitingPhase 2

A Phase 2, Open-Label, Safety Lead-In with Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients.
A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

Start Date01 Aug 2025

Sponsor / Collaborator

Evergreen Therapeutics, Inc

NCT04901741 / Not yet recruitingPhase 2

An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients

The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.

Start Date01 Jun 2025

Sponsor / Collaborator

TME Pharma NV

[+1]

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

9,182

Literatures (Medical) associated with Pembrolizumab

01 Feb 2025·Current Gene Therapy

Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Alimohammadi, Mina ; Mousavi, Tahoora ; Araghi, Mahmood ; Soleimantabar, Hussein ; Gharebakhshi, Farshad ; Mafi, Alireza ; Faramarzi, Fatemeh

Background:Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC.Methods:To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models.Results:According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune- related adverse events of 22.7%.Conclusion:A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.

01 Jan 2025·Clinical Oncology

Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab

Article

Author: Tookman, L. ; Tookman, L ; Patel, A ; Counsell, N. ; Eminowicz, G. ; Nicum, S. ; Eminowicz, G ; Mahalingam, Preethika ; Nicum, Shibani ; Mahalingam, P. ; Counsell, Nicholas ; Senthivel, N ; Browne, R ; Usman, Sadaf ; Nicum, S ; Patel, A. ; Turnbull, E ; Usman, S ; Eminowicz, Gemma ; Ramessur, A. ; Mahalingam, P ; Ramessur, Anisha ; Miller, R ; Pawsey, A ; Stewart, Alexandra ; Stewart, A. ; Ramessur, A ; Stewart, A ; Turnbull, Emily ; Patel, Apini ; Counsell, N ; Turnbull, E. ; Senthivel, Nishanthi ; Browne, R. ; Pawsey, Alexander ; Usman, S. ; Miller, Rowan ; Tookman, Laura ; Pawsey, A. ; Browne, Riona ; Miller, R. ; Senthivel, N.

AIMSPatients with endometrial cancer who progress following first line therapy have improved survival outcomes with pembrolizumab and lenvatinib (pem/len) compared with standard of care chemotherapy, as demonstrated in KEYNOTE-775. This was in a group of trial patients with good performance status and excluded those with carcinosarcoma histology. In KEYNOTE-775 pem/len was associated with significant toxicity, leading to dose reductions, treatment cessation, and patient morbidity. We set out to assess the tolerability, toxicity and outcomes following pem/len for patients with recurrent, advanced or metastatic endometrial cancer in a real-world setting.MATERIALS AND METHODSUK centres treating patients with pem/len for advanced endometrial cancer within the compassionate access programme were approached. Retrospective data were analysed for those treated between May 2022 and June 2023. Data on patient demographics, treatment, toxicity and outcomes were extracted from medical records. Toxicity and tolerability were compared in those over and under the age of 70.RESULTSSeven centres returned data for 70 patients. Median age of patients was 68.5 years (range 45-85) with a performance status of 0-1 in 77.1% and of 2 in 22.9%. Histological subtypes included serous (34.3%), endometrioid (32.9%), carcinosarcoma (14.3%), clear cell (7.1%), mixed (2.9%) and other (8.6%). Grade ≥3 toxicity was reported in 55.7% with any-grade toxicity observed in 85.7%. In those aged ≥70 years (n = 30) the rate of grade ≥3 toxicity was 60.0%. Rates of dose reduction of lenvatinib were 64.3%, and toxicity-related treatment interruption was 45.7%. The 6-month progression-free and overall survival rates were 54.0% (95%CI: 39.0-66.8) and 70.1% (95%CI:56.5-80.1) respectively.CONCLUSIONThis real-world, observational study of pem/len showed comparable tolerability, toxicity, and outcomes to previously reported clinical trial data. Our cohort included patients with a poorer PS and a broader range of histological subtypes including carcinosarcoma.

01 Jan 2025·Current Cancer Drug Targets

Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer

Article

Author: Paglialunga, Luca ; Pillozzi, Serena ; Antonuzzo, Lorenzo ; Fancelli, Sara ; Petrella, Maria Cristina ; Caliman, Enrico ; Roviello, Giandomenico ; Grosso, Anna Maria ; Rossi, Virginia ; Comin, Camilla Eva ; Mazzoni, Francesca

Background:Emerging evidence identified sex as a variable regulating immune system functions and modulating response to immunotherapy in cancer patients.Objective:This retrospective study analysed sex-related differences in immunotherapy outcomes in a real-world population of non-small cell lung cancer (NSCLC) patients treated with immune check-point inhibitors (ICIs).Methods:We retrospectively investigated clinical data of 99 patients with advanced NSCLC and treated with single-agent nivolumab and pembrolizumab at Medical Oncology Unit, Careggi Universi-ty Hospital, Florence (Italy), between April 2014 to August 2019. Main clinical characteristics and clinical outcomes were analysed.Results:Our study showed that the efficacy of ICI treatment differed according to gender. A trend for better median progression-free survival (mPFS) was reported in males (mPFS 5.0 months, 95% Con-fidence Interval [CI] 4.0-11.0) than females (mPFS 4.5 months, 95% CI 2.0-9.0) (p=0.133), while no significant difference for overall survival (OS) between the two sex groups was observed (p=0.622). In the nivolumab cohort, we showed a statistically significant difference for a longer PFS in men compared to women (log-rank p=0.054), HR for PFS in females versus males was 1.81 (95% CI 0.97-3.37, p=0.062). Disease control rate (DCR) was achieved in 55.7% and 45.7% of men and women, respectively, while disease progression was registered in 44.3% of males and 54.3% of females (p=0.386).Conclusions:Gender is a variable that should be taken into account in the choice of immunotherapy. Future prospective randomized trials testing tailored sex-based immunotherapy strategies are required to validate our findings before integrating into clinical practice.

4,441

News (Medical) associated with Pembrolizumab

19 Nov 2024

·www.prnewswire.com

Dwight Owen, MD, Receives Research Award for Innovative Approach to Overcoming Immunotherapy Resistance

Award lays the foundation for the next generation of immunotherapy breakthroughs WASHINGTON, Nov. 19, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to announce the recipient of the 2024 Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy. In the past decade, immunotherapies based on blocking the PD-(L)1 and the CTLA-4 pathways have been major breakthroughs in the treatment of lung cancer. However, tumors typically develop resistance to treatment and begin to grow again. This award, generously supported by the Brown Family from Atlanta, GA, is dedicated to pioneering research into the underlying mechanisms of non-small cell lung cancer (NSCLC) resistance to immunotherapy, with the goal of developing interventions to eliminate drug resistance and prolong the effectiveness of immunotherapy. "Our family experienced the positive impact of immunotherapy. Unfortunately, like so many others, our response was not as lasting as we had hoped," said Mike Brown. "With this research award, our goal is to support research that will help not only our family but also those who may face resistance to immunotherapy in the future." The recipient of the 2024 Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy is: Researcher: Dwight Owen, MD Institution: Ohio State University Project: Targeting Tumor-Associated Macrophages in Immunotherapy-Resistant NSCLC Dr. Owen aims to tailor the body's natural defense mechanisms to improve the effectiveness and duration of immunotherapy treatment. This research team aims to deepen our understanding of the role of tumor-associated macrophages (TAMs) – immune cells that are thought to promote tumor development and metastasis. The researchers will study hedgehog signaling, an important protein pathway that is likely to be involved in the crosstalk between TAMs, other parts of the immune system, and NSCLC cells. By disrupting hedgehog signaling in TAMs, Dr. Owen and his team aim to create an environment that is less favorable for cancer cell survival, allowing patients' immune systems to effectively combat the disease and overcome drug resistance to immunotherapy in NSCLC. "With the introduction of immune checkpoint inhibitors, the cancer community understood the power of removing obstacles for the patient's natural immune system," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research. "However, acquired resistance is an issue in a major subset of patients. We are proud to partner with the Brown Family on this award to develop a novel opportunity to prolong the benefits of immunotherapy in NSCLC." About LUNGevity Foundation LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. Through research, we use an innovative and holistic approach to finding lung cancer earlier when it is most treatable; advance research into new treatments so people may live longer and better; and ensure a diverse, vital pipeline of investigators for the future of the lung cancer field. Through advocacy, we foster groundbreaking collaborations to ensure all people have access to screening, biomarker testing, and treatment breakthroughs. Through community, we educate, support, and connect people affected by lung cancer so that they can get the best healthcare and live longer and better lives. Comprehensive resources include a medically vetted and patient-centric website, Patient Gateways for specific types of lung cancer, a toll-free HELPLine for personalized support, international survivor conferences, and tools to find a clinical trial. All these programs are designed to help us achieve our vision—a world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization. Please visit to learn more. About Lung Cancer in the US About 1 in 18 Americans will be diagnosed with lung cancer in their lifetime. More than 234,000 people in the US will be diagnosed with lung cancer this year, with a new diagnosis every 2.2 minutes. It is estimated that close to 65% of all new lung cancer diagnoses are among people with no tobacco exposure or only past tobacco exposure. More lives are lost to lung cancer than to the next two deadliest cancers (colorectal and pancreatic) combined. Only 27% of all people diagnosed with lung cancer will survive 5 years or more, but if it's caught before it spreads, the chance of 5-year survival improves to 64%. SOURCE LUNGevity Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Immunotherapy

19 Nov 2024

·firstwordpharma.com

Merck & Co.'s subcutaneous version of Keytruda succeeds in pivotal lung cancer study

Merck & Co. said Tuesday that a subcutaneous formulation of Keytruda (pembrolizumab) was non-inferior to the currently-approved intravenous version when used alongside chemotherapy for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC). "We plan to discuss these results with regulatory authorities worldwide as soon as possible," indicated Marjorie Green, head of oncology, global clinical development at Merck Research Laboratories. The subcutaneous formulation — referred to as MK-3475A — pairs Merck's anti-PD-1 therapy with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen. "It is very encouraging to see positive Phase III results evaluating this fixed-dose combination of subcutaneous pembrolizumab, which was administered, on average, in approximately 2-3 minutes and has the potential to improve the patient experience as well as increase access for patients and healthcare providers," Green remarked.In the trial, MK-3475A administered every six weeks with chemotherapy demonstrated non-inferiority of Area Under the Curve (AUC) exposure of pembrolizumab during the first dosing cycle, and trough concentration measured at steady state, compared to intravenous Keytruda. Merck added that secondary endpoints of efficacy and safety were "generally consistent" for the subcutaneous and intravenous formulations.

Clinical ResultPhase 3

18 Nov 2024

·pipelinereview.com

Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 Human Papillomavirus-Associated Cancers

— No safety issues and evidence of early activity for TGN-S11 identified as a monotherapy through 3 completed cohorts in Part 1 and in combination therapy with Keytruda® in the first completed level in Part 2 SAN DIEGO, CA, USA I November 18, 2024 I Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its ongoing Phase 1 trial of TGN-S11, its small molecule drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being conducted in two parts: Part 1 is escalating doses of TGN-S11 monotherapy and Part 2 is TGN-S11 in combination with Keytruda®, a PD-1 checkpoint inhibitor. The dose escalation part consists of up to five Cohorts of three to six patients on monotherapy with increasing doses of TGN-S11. The Keytruda® combination part consists of up to five Levels of three to six patients with increasing doses of TGN-S11 and the standard dose of Keytruda®. In Part 1, 9 patients were treated with TGN-S11 as monotherapy in the first 3 dose cohorts with no safety issues identified. One-third of the patients in this portion of the study showed drug activity with decreases in tumor size and decreases in circulating tumor HPV DNA (ctHPV DNA). In addition, three patients have been treated in Part 2 Level 1 evaluating TGN-S11 in combination with Keytruda® with no safety issues. Two of these 3 patients in this portion of the study showed drug activity with decreases in tumor size and decreases in circulating tumor HPV DNA. One of these 3 patients continues to receive combination therapy and has a 93% reduction in ctHPV DNA. The study is ongoing with patients currently being dosed in Part 1 Cohort 4 and Part 2 Level 2. “We have been very pleased with the positive safety profile for TGN-S11 in patients who completed the first 3 monotherapy dose cohorts of Part 1 and the first level of Part 2 in combination with Keytruda® in this ongoing Phase 1 trial,” said Dr. Sandra Coufal, Toragen’s CEO. “The drug activity observed in 5 of these 12 subjects is also very encouraging. Based on the current progress, we believe both parts of the study will be completed by the end of 2024.” About Toragen Toragen, a clinical-stage biotechnology company based in San Diego, California, has the only HPV E5 protein inhibitor in human clinical trials. https://toragen.com . SOURCE: Toragen

Phase 1Clinical Result

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced Renal Cell Carcinoma	LI	Merck Sharp & Dohme BV	17 Jul 2015
Advanced Renal Cell Carcinoma	IS	Merck Sharp & Dohme BV	17 Jul 2015
Advanced Renal Cell Carcinoma	NO	Merck Sharp & Dohme BV	17 Jul 2015
Advanced Renal Cell Carcinoma	EU	Merck Sharp & Dohme BV	17 Jul 2015
Gastroesophageal junction adenocarcinoma	IS	Merck Sharp & Dohme BV	17 Jul 2015
Gastroesophageal junction adenocarcinoma	LI	Merck Sharp & Dohme BV	17 Jul 2015
Gastroesophageal junction adenocarcinoma	EU	Merck Sharp & Dohme BV	17 Jul 2015
Gastroesophageal junction adenocarcinoma	NO	Merck Sharp & Dohme BV	17 Jul 2015
HER2 negative Gastroesophageal Junction Adenocarcinoma	LI	Merck Sharp & Dohme BV	17 Jul 2015
HER2 negative Gastroesophageal Junction Adenocarcinoma	NO	Merck Sharp & Dohme BV	17 Jul 2015
HER2 negative Gastroesophageal Junction Adenocarcinoma	IS	Merck Sharp & Dohme BV	17 Jul 2015
HER2 negative Gastroesophageal Junction Adenocarcinoma	EU	Merck Sharp & Dohme BV	17 Jul 2015
Locally Advanced Lung Non-Small Cell Carcinoma	IS	Merck Sharp & Dohme BV	17 Jul 2015
Locally Advanced Lung Non-Small Cell Carcinoma	LI	Merck Sharp & Dohme BV	17 Jul 2015
Locally Advanced Lung Non-Small Cell Carcinoma	NO	Merck Sharp & Dohme BV	17 Jul 2015
Locally Advanced Lung Non-Small Cell Carcinoma	EU	Merck Sharp & Dohme BV	17 Jul 2015
Unresectable Melanoma	EU	Merck Sharp & Dohme BV	17 Jul 2015
Unresectable Melanoma	LI	Merck Sharp & Dohme BV	17 Jul 2015
Unresectable Melanoma	IS	Merck Sharp & Dohme BV	17 Jul 2015
Melanoma	US	Merck Sharp & Dohme LLC	04 Sep 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uterine Cervical Cancer	NDA/BLA	CN	Merck Sharp & Dohme LLC	04 Apr 2024
Transitional Cell Carcinoma	NDA/BLA	CN	Merck Sharp & Dohme LLC	28 Mar 2024
Recurrent Endometrial Cancer	NDA/BLA	US	Merck Sharp & Dohme Corp.	21 Feb 2024
ER-positive/HER2-negative Breast Cancer	NDA/BLA	CN	Merck Sharp & Dohme LLC	08 Nov 2023
Locally Advanced Cholangiocarcinoma	NDA/BLA	US	Merck & Co., Inc.	08 Jun 2023
Metastatic Biliary Tract Carcinoma	NDA/BLA	US	Merck & Co., Inc.	08 Jun 2023
Unresectable Biliary Tract Carcinoma	NDA/BLA	US	Merck & Co., Inc.	08 Jun 2023
Small intestine carcinoma	NDA/BLA	EU	Merck Sharp & Dohme Corp.	25 Mar 2022
Stomach Cancer	NDA/BLA	EU	Merck Sharp & Dohme Corp.	25 Mar 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Hodgkin's Lymphoma	-	Pembrolizumab 200 mg	xappkuvyoq(wyqcwlhyzh) = led to discontinuations in 2 patients (at 2 and 6 months) ceohqgysjc (cbckookrqc ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Classical Hodgkin's Lymphoma	-	Pembrolizumab plus AVD and RT	uziohzfsob(xqwsfsgjmo) = treatment-related adverse events (AEs) were reported in 8 patients (80%); grade 3 or 4 treatment-related AEs occurred in 4 patients (40%). No patients discontinued or died due to treatment-related AEs. Seven patients (67%) had pembrolizumab-related AEs, 3 of whom (30%) had a grade 3 event (vomiting, lymphocyte count decreased, white blood cell count decreased). Immune-mediated AEs occurred in 3 patients (30%; all grade 1 or 2 hypothyroidism) cnybaicbgb (mtyfxtupku )	-	08 Dec 2024
ASH2024	Not Applicable	Classical Hodgkin's Lymphoma	-	Pembrolizumab plus COPDAC-28 with RT	(fcvfhhakbw) = dupzlxfork pnllhcqcjs (auqyauckqu, 93 - 100) View more	-	08 Dec 2024
				Pembrolizumab plus COPDAC-28 without RT	ygtgudomyj(rjnkrwqzob) = rluqjxiifs uvmvqgxljr (nugpduebmp )
NCT02844075 (CTgov)	Phase 2	Esophageal Squamous Cell Carcinoma	28	MK-3475(pembrolizumab)	hmnhryrcuo(ffmezfgyit) = fvqangqkcn jlhwapknwe (tdhweoavce, onhjytlaiu - yrjdozxosk) View more	-	15 Nov 2024
NCT03769467 (CTgov)	Phase 1/2	EBV viremia \| Epstein-Barr Virus Infections \| Nasopharyngeal Carcinoma \| Epstein-Barr virus associated Nasopharyngeal Carcinoma	12	Pembrolizumab+Tabelecleucel (Cohort 1B: Checkpoint Inhibitor Naïve)	woworgapis(nhawwdgawl) = jegdfdkaoi zyfrrlijtp (yghcbnthqu, azmbikbolf - zmdgvseeuh) View more	-	14 Nov 2024
				Pembrolizumab+Tabelecleucel (Cohort 1B: Checkpoint Inhibitor PD-1/PD-L1 Failure)	woworgapis(nhawwdgawl) = taohgqppbb zyfrrlijtp (yghcbnthqu, waxkyzdqxi - wkvohlyqtq) View more
NCT04135352 (V938-001, CTgov)	Phase 1	Neoplasms	35	200 mg of pembrolizumab+V938 (Dose Expansion Arm A, Melanoma)	ylcvseihoc(wrdswemjjv) = xinxmfxbuv gudknhryrt (koxtfdbvyf, kijevppnku - dtfnbkssbs) View more	-	12 Nov 2024
				200 mg of pembrolizumab+V938 (Dose Expansion Arm B, HNSCC)	ylcvseihoc(wrdswemjjv) = ppcipfrnsk gudknhryrt (koxtfdbvyf, wgnnooqiva - wqqawyzjsw) View more
NCT03630042 (PembroWM, CTgov)	Phase 2	Waldenstrom's macroglobulinaemia refractory	17	pembrolizumab+Rituximab	noayhnzixn(fytcevqkph) = ymdgvnlzil hcciyswynq (azdngqviaj, sonhpyiovc - tdfnpqfeex) View more	-	07 Nov 2024
NCT04581824 (PERLA, SITC2024) Manual	Phase 2	Non-squamous non-small cell lung cancer	243	Dostarlimab + CT	(euirzossds) = zetpfjruun azancgfiox (bbmrvumygf, 14.5 - 27.3)	Positive	05 Nov 2024
				Pembrolizumab + CT	(euirzossds) = rqtovhmwfd azancgfiox (bbmrvumygf, 11.6 - 19.3)
NCT05200559 (SITC2024) Manual	Phase 1	Solid tumor	16	E7777 + pembrolizumab	(ptkkhmxwpt) = no DLTs were noted in DL 1 (3 mcg/kg) n=3, DL2 (6 mcg/kg) n=2, and DL3 (9 mcg/kg) n=2. One patient experienced a DLT at in DL4 (12 mcg/kg) n=9 and she was able to safely continue treatment. vmfhwendxt (ulqinldzlr ) View more	Positive	05 Nov 2024
NCT05708950 (VISTA-101, SITC2024) Manual	Phase 1/2	Advanced Malignant Solid Neoplasm	30	KVA12123	(chmeocifra) = None meffbkrrsg (ltzqogckmj ) View more	Positive	05 Nov 2024
				KVA12123 + pembrolizumab